CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011
Cash flows from operating activities:
Net loss	$ (4,725)	$ (7,555)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	28	122
Amortization of intangible assets	118	0
Accretion of convertible note discount	199	0
Amortization of deferred financing costs	125	0
Loss on extinguishment of convertible note	338	0
Stock-based compensation expense	753	247
Warrant expense	141	0
Fair value of warrant liability	(557)	0
Write-off of obsolete inventory	56	0
Loss on disposal of property and equipment	2	118
Assignment of Medicsight's stock to D4D	0	(4)
Gain on sale of Moneygate	0	(81)
(Increase)/decrease in assets:
Accounts receivable	75	(40)
Other receivables - related party	0	47
Proceeds from release of security deposits	201	0
Restricted cash	(39)	0
Prepaid expenses and other current assets	(13)	402
Inventory	36	(89)
Increase / (decrease) in liabilities:
Accounts payable	29	(296)
Accrued expenses	(230)	(421)
Other payables	(4)	(85)
Net cash used in operating activities	(3,467)	(7,635)
Cash flows from investing activities:
Purchase of property and equipment	(17)	(13)
Repurchase of Medicsight's shares	(33)	0
Purchase of intangible asset	(200)	0
Repayment of Dunamis loan	0	1,100
Receipts from sale of Moneygate	0	401
Receipts of deferred consideration for sale of assets	0	370
Receipts from sale of Medicsight's stock	0	110
Net cash (used in) / provided by investing activities	(250)	1,968
Cash flows from financing activities:
Sale of common stock	0	639
Cash paid in lieu of fractional shares in reverse/forward split	(5)	0
Proceeds from issuance of convertible note	3,500	0
Payments for convertible note issuance costs	(372)	0
Repayment of convertible note	(3,500)	0
Proceeds from issuance of preferred stock	4,500	0
Proceeds from issuance of common stock, net	1,316	0
Restricted cash	(2,000)	0
Net cash provided by financing activities	3,439	639
Effects of exchange rates on cash and cash equivalents	17	298
Net change in cash and cash equivalents	(261)	(4,730)
Cash and cash equivalents, beginning of period	3,704	8,434
Cash and cash equivalents, end of period	3,443	3,704
Supplemental cash disclosures:
Cash paid for interest on convertible note	93	0
Supplemental non-cash disclosures (investing and financing activities):
Stock issued for services in connection with issuance of convertible note	315	0
Stock issued for services in connection with extinguishment of convertible note	415	0
Warrants issued in connection with acquisition of intangible assets	851	0
Warrants issued in connection with issuance of convertible note	500	0
Beneficial conversion on issuance of convertible note	500	0
Beneficial conversion on extinguishment of convertible note	1,341	0
Intangible asset contributed by non-controlling interest	862	0
Stock issued for purchase of Medicsight Ltd ordinary shares	418	0
Dividends issued on Convertible Preferred Series A Stock	47	0
Warrant - Deemed Dividend (in excess of proceeds received)	$ 2,231	$ 0